The Effects of gonadotropin-releasing hormone analog and a combination of gonadotropin-releasing hormone analog and recombinant human growth hormone on adult height in girls with early puberty

Authors
Ghodsieh Hajzadeh 1
Norsrat Ghaemi 1
Mousa-Al-Reza Hadjzadeh 2
Samaneh Noroozi 1
Negar Morovatdar 3
1 Department of Pediatric Endocrinology and Metabolism, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Department of Physiology, School of Medicine; Division of Neurocognitive Sciences, Psychiatry and Behavioral Sciences Research Center; Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
3 Clinical Research Unit, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract
Background: Early puberty (EP) is due to the activation of gonadotropin-releasing hormone (GnRH) pulse generator in lower ages; EP may be a potential cause for impairment of adult height, leading to short stature. The aim of this study was to determine the effects of GnRH analog (GnRHa) and GnRHa plus recombinant human growth hormone (rhGH) treatment on final height in healthy girls with EP. Materials and Methods: Fifty EP girls (sexual maturity rating: 2–3) with chronological age (CA) 9.22 ± 0.56 and bone age (BA) 9.74 ± 0.59 years were treated with GnRHa (Triptorelin) at a dose of 100 μg/kg body weight (BW) as intramuscular every 28 days for 2.82 ± 0.57 years; 45 EP girls with CA 9.84 ± 0.57 and BA 10.14 ± 1.02 years were also treated with the same GnRHa plus rhGH (Norditropin) at a dose of 0.1 unit/kg BW daily for 6 days in a week for 2.55 ± 0.6 years. In the control group, 33 EP girls followed for the same period without treatment. Height, weight, and body mass index of girls and parents were assessed. Predicted adult height (PAH) at the start and the end of the study and target height were assessed.Results: PAH at the end of the study in the GnRHa group was not different with untreated girls. PAH at the end of the treatment in GnRHa plus rhGH group was significantly higher than both untreated and GnRHa group. PAH at the end of therapy in GnRHa plus rhGH group was significantly more than their target height. Conclusion: GnRHa therapy has a benefit effect in achievement of target height. Combination therapy with GnRHa plus rhGH increased their PAH more than both untreated and GnRHa groups.

Keywords

1.
Kliegman RM, Lye PS, Bordini BJ, Toth H, Basel D. Nelson Pediatric Symptom-Based Diagnosis E-Book. Philadelphia: Elsevier Health Sciences; 2016.  Back to cited text no. 1
    
2.
Ying Y, Tang J, Chen W, Cai Z, Niu WT. GnRH agonist treatment for idiopathic central precocious puberty can improve final adult height in Chinese girls. Oncotarget 2017;8:109061-7.  Back to cited text no. 2
    
3.
Brook CG, Clayton P, Brown R, editors. Brook's Clinical Pediatric Endocrinology: Massachusetts. John Wiley & Sons; 2006.  Back to cited text no. 3
    
4.
Lin YC, Lin CY, Chee SY, Yen HR, Tsai FJ, Chen CY, et al. Improved final predicted height with the injection of leuprolide in children with earlier puberty: A retrospective cohort study. PLoS One 2017;12:e0185080.  Back to cited text no. 4
    
5.
Song W, Zhao F, Liang S, Li G, Xue J. Is a combination of a GnRH agonist and recombinant growth hormone an effective treatment to increase the final adult height of girls with precocious or early puberty? Int J Endocrinol 2018;2018:1708650.  Back to cited text no. 5
    
6.
Li P, Li Y, Yang CL. Gonadotropin releasing hormone agonist treatment to increase final stature in children with precocious puberty: A meta-analysis. Medicine (Baltimore) 2014;93:e260.  Back to cited text no. 6
    
7.
Bertelloni S, Massart F, Miccoli M, Baroncelli GI. Adult height after spontaneous pubertal growth or GnRH analog treatment in girls with early puberty: A meta-analysis. Eur J Pediatr 2017;176:697-704.  Back to cited text no. 7
    
8.
Toumba M, Kokotsis V, Savva SC, Skordis N. Expensive therapies in children: Benefit versus cost of combined treatment of recombinant human growth hormone and gonadotropin-releasing hormone analogue in girls with poor height potential. J Pediatr Endocrinol Metab 2014;27:311-6.  Back to cited text no. 8
    
9.
Tanaka T, Satoh M, Yasunaga T, Horikawa R, Tanae A, Hibi I, et al. GH and GnRH analog treatment in children who enter puberty at short stature. J Pediatr Endocrinol Metab 1997;10:623-8.  Back to cited text no. 9
    
10.
Toumba M, Bacopoulou I, Savva SC, Skordis N. Efficacy of combined treatment with growth hormone and gonadotropin releasing hormone analogue in children with poor prognosis of adult height. Indian Pediatr 2007;44:497-502.  Back to cited text no. 10
    
11.
Wang CZ, Guo LL, Han BY, Wang AP, Liu HY, Su X, et al. Growth hormone therapy benefits pituitary stalk interruption syndrome patients with short stature: A retrospective study of 75 Han Chinese. Int J Endocrinol 2016;2016:1896285.  Back to cited text no. 11
    
12.
Demirkale ZH, Abali ZY, Bas F, Poyrazoglu S, Bundak R, Darendeliler F. Comparison of the clinical and anthropometric features of treated and untreated girls with borderline early puberty. J Pediatr Adolesc Gynecol 2019;32:264-70.  Back to cited text no. 12
    
13.
Kletter GB, Kelch RP. Clinical review 60: Effects of gonadotropin-releasing hormone analog therapy on adult stature in precocious puberty. J Clin Endocrinol Metab 1994;79:331-4.  Back to cited text no. 13
    
14.
Brauner R, Adan L, Malandry F, Zantleifer D. Adult height in girls with idiopathic true precocious puberty. J Clin Endocrinol Metab 1994;79:415-20.  Back to cited text no. 14
    
15.
Chiavaroli V, Liberati M, D'Antonio F, Masuccio F, Capanna R, Verrotti A, et al. GNRH analog therapy in girls with early puberty is associated with the achievement of predicted final height but also with increased risk of polycystic ovary syndrome. Eur J Endocrinol 2010;163:55-62.  Back to cited text no. 15
    
16.
Karamizadeh Z, Kashef MA, Jalaeian H, Namazee N. Combined use of growth hormone and gonadotropin-releasing hormone analogue in short normal adolescent girls: A survey from Iran. Kaohsiung J Med Sci 2006;22:161-5.  Back to cited text no. 16
    
17.
Cassio A, Cacciari E, Balsamo A, Bal M, Tassinari D. Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years. Arch Dis Child 1999;81:329-32.  Back to cited text no. 17
    
18.
Pucarelli I, Segni M, Ortore M, Moretti A, Iannaccone R, Pasquino AM. Combined therapy with GnRH analog plus growth hormone in central precocious puberty. J Pediatr Endocrinol Metab 2000;13 Suppl 1:811-20.  Back to cited text no. 18
    
19.
Wang CL, Liang L, Liu PN, Jin XJ, Chen LQ, Yang F, et al. Effects of gonadotropin releasing hormone analog and growth hormone on height in girls with idiopathic central precocious puberty. Zhongguo Dang Dai Er Ke Za Zhi 2014;16:25-30.  Back to cited text no. 19
    
Advanced Biomedical Research
Volume 2019, september
September 2019
Pages 1-6